Kurse werden geladen...
Prognose
| Kaufen | 1 |
| Halten | 3 |
| Verkaufen | 0 |
Scoring-Modelle
| Dividenden-Strategie | 0 / 15 |
| HGI-Strategie | 0 / 18 |
| Levermann-Strategie | -6 / 13 |
News
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum's newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.» Mehr auf globenewswire.com
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets.» Mehr auf globenewswire.com
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics 9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | −316,13k | 4.774,04% |
| Nettoeinkommen | −4,52 Mio | 31,29% |
| EBITDA | −3,43 Mio | 43,57% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 32,73 Mio€ |
Anzahl Aktien | 40,00 Mio |
52 Wochen-Hoch/Tief | 2,56€ - 0,69€ |
| Dividenden | Nein |
Beta | 2,82 |
KGV (PE Ratio) | −1,45 |
KGWV (PEG Ratio) | −0,06 |
KBV (PB Ratio) | −12,85 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Iterum Therapeutics plc, ein pharmazeutisches Unternehmen in der klinischen Phase, entwickelt und vermarktet Antiinfektiva in Irland, Bermuda und den Vereinigten Staaten. Das Unternehmen entwickelt Sulopenem, ein neuartiges Antiinfektivum mit oraler und intravenöser Formulierung, das sich in klinischen Phase-III-Studien zur Behandlung von unkomplizierten Harnwegsinfektionen, komplizierten Harnwegsinfektionen und komplizierten intraabdominalen Infektionen befindet. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Dublin, Irland.
| Name | ITERIUM THERAP. EO-,01 |
| CEO | Corey N. Fishman |
| Sitz | Dublin, Irland |
| Website | |
| Industrie | Chemikalien |
| Börsengang | |
| Mitarbeiter | 9 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | ITRM |
Assets entdecken
Shareholder von ITERIUM THERAP. EO-,01 investieren auch in folgende Assets
